Data as of Apr 17
| +0.17 / +0.39%|
The 28 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 49.27, with a high estimate of 60.73 and a low estimate of 31.45. The median estimate represents a +11.59% increase from the last price of 44.15.
The current consensus among 31 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.